Stay updated on Galidesivir Safety/PK/Antiviral Effects in Yellow Fever/COVID-19 Clinical Trial
Sign up to get notified when there's something new on the Galidesivir Safety/PK/Antiviral Effects in Yellow Fever/COVID-19 Clinical Trial page.

Latest updates to the Galidesivir Safety/PK/Antiviral Effects in Yellow Fever/COVID-19 Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed information about a Phase II study on the combination of lenvatinib and pembrolizumab for treating metastatic gastroesophageal cancer, while adding a new revision number and a specific study identifier.SummaryDifference49%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check88 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check95 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to Galidesivir Safety/PK/Antiviral Effects in Yellow Fever/COVID-19 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Galidesivir Safety/PK/Antiviral Effects in Yellow Fever/COVID-19 Clinical Trial page.